Remove In-Vivo Remove Protein Remove Reagent Remove Scientist
article thumbnail

Turning science into business: An optimised alternative to antibodies

Drug Discovery World

As a business of scientists, we remain passionate about the exciting developments in the industry, from research to precision therapies, and insatiably curious about the new possibilities that can be achieved by overcoming the limits of standard research tools and methods. DDW’s Diana Spencer caught up with co-founder and CEO Dr Arron Tolley.

article thumbnail

Receptor Occupancy Assays by Flow Cytometry: Benefits for Clinical Trials

XTalks

Receptor occupancy assays have been developed and applied in both nonclinical and clinical studies to provide insight into PK/PD relationships so far,” said Andre Olsson, PhD, Senior Scientist, Flow Cytometry at the global contract research organization (CRO) Medpace. What is Flow Cytometry?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Reflecting on PEGS Europe 2023 

Drug Discovery World

This presentation covered three primary drivers for a protein expression model: speed, cost and sustainability. “It The next presentation attended in this track was the keynote presentation, which was given by Kate Smith, PhD, Head of UK Protein & Cell Sciences at GSK. GSK has developed high-throughput mammalian and E.

article thumbnail

Fortis Life Sciences leads the way in custom antibody discovery

Drug Discovery World

Moreover, custom antibodies are a key reagent in companion diagnostics for these novel therapeutics. Custom antibodies can be developed for pharmacokinetic assays and biodistribution assays, supporting therapeutic development by giving researchers data about the behaviour of their novel therapeutic in vivo.

article thumbnail

CRISPR breakthroughs: New solutions for common diseases

Drug Discovery World

Current research is focused on designing CRISPR-enhanced CAR T cells that are resistant to immunosuppressive cytokines such as transforming growth factor-β (TGF-β) 2 , programmed cell death protein (PD-1) 3 , or other negative T cell regulators 4 (CTLA-4, LAG-3, and TIM-3), thus improving anti-tumour functions.

DNA 98
article thumbnail

Flow cytometry technologies and cancer associated fibroblasts

Drug Discovery World

Dr Amber Miller, Flow Cytometry Scientist, Fortis Life Sciences, says flow cytometry techniques can help our understanding of cancer associated fibroblasts but there is still work to be done. Fibroblasts in the tumour microenvironment. Cancer associated fibroblasts (CAFs) have recently emerged as key players in the tumour microenvironment.